GSE193351 4 V 0 RUXOLITINIB HUMAN DN (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE193351 4 V 0 RUXOLITINIB HUMAN DN.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE193351 4 V 0 RUXOLITINIB HUMAN DN.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE193351 4 V 0 RUXOLITINIB HUMAN DN.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE193351 4 V 0 RUXOLITINIB HUMAN DN.

Results found

Linked to

 

Label

Description

 

Gene

NBPF member 26

Gene

tripartite motif containing 31

Gene

contactin associated protein family member 3C

Gene

nuclear pore complex interacting protein family member A9

Gene

neuropeptide Y receptor Y4-2

Gene

suppressor APC domain containing 1

Gene

family with sequence similarity 90 member A11

Gene

ATF7-NPFF readthrough

Gene

family with sequence similarity 90 member A15

Gene

corin, serine peptidase


  • Gene

    tripartite motif containing 31


  • Gene

    contactin associated protein family member 3C


  • Gene

    nuclear pore complex interacting protein family member A9


  • Gene

    neuropeptide Y receptor Y4-2


  • Gene

    suppressor APC domain containing 1


  • Gene

    family with sequence similarity 90 member A11


  • Gene

    ATF7-NPFF readthrough


  • Gene

    family with sequence similarity 90 member A15


  • Gene

    corin, serine peptidase

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.